Nasdaq
$1.24▲ 0.40%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.2MShares out 4.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
34- 4d agoPre-market26.10.21 21:158-KKey event#●●●#●●●
Imunon, Inc.
Imunon has entered into an agreement to sell its ThermoDox assets to VoxelDox Therapeutics. The transaction is contingent upon VoxelDox raising at least $2.5 million, and upon closing, Imunon will receive a 4.76% equity stake in VoxelDox along with up to $16.5 million in potential milestone payments and royalties.…more
$1.24+0.40%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 05:084Ownership
Imunon, Inc.
Insider Michael H. Tardugno of Imunon, Inc. reported a change in beneficial ownership of securities as of October 9, 2026. This filing is a Form 4 statement submitted to the SEC regarding the insider's equity transaction.…more
$1.24+0.40%vs prev closeView filingShare - 10.13After-hours26.10.14 05:064Ownership
Imunon, Inc.
Insider Stacy Lindborg of Imunon, Inc. reported a change in beneficial ownership of securities effective October 9, 2026. This filing is a Form 4 statement submitted to the SEC regarding executive equity holdings.…more
$1.24+0.40%vs prev closeView filingShare
33 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 21:15#●●●#●●●#●●●
IMUNON Announces Strategic Sale of ThermoDox to VoxelDox
IMUNON has agreed to sell its rights to the cancer drug candidate ThermoDox to VoxelDox Therapeutics in exchange for equity and milestone payments. The company intends to focus its resources on its lead clinical program, the Phase 3 trial of IMNN-001.…more
$1.24+0.40%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.8Pre-market26.10.08 22:00
●●●●●●●● ●●●●● ●●●●●●
IMUNON announced that its CEO will participate in the Maxim Growth Summit and the ThinkEquity Conference in October. This is a routine investor relations activity and does not provide immediate material impact on the stock.…more
$1.24+0.40%vs prev close - 9.29Pre-market26.09.29 21:04
●●●●●●●● ●●●●● ●●●●●●
Imunon announced the exchange of $1.2 million in debt for non-convertible Series B preferred stock. This move is intended to improve the company's capital structure by reducing debt obligations.…more
$1.24+0.40%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report